Goo Taeg Oh Selected Research

Fenofibrate (CiL)

11/2022	Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
12/2019	Impaired Peroxisomal Fitness in Obese Mice, a Vicious Cycle Exacerbating Adipocyte Dysfunction via Oxidative Stress.
1/2013	Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2.
10/2004	Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice.
5/2004	Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice.
2/2003	Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice.
12/2002	Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Goo Taeg Oh Research Topics

Disease

37	Atherosclerosis 01/2023 - 05/2002
17	Inflammation (Inflammations) 11/2022 - 11/2004
9	Obesity 01/2021 - 12/2002
9	Neoplasms (Cancer) 01/2020 - 06/2008
8	Atherosclerotic Plaque (Atheroma) 05/2023 - 10/2004
7	Body Weight (Weight, Body) 10/2020 - 12/2002
6	Infections 01/2023 - 01/2002
6	Cardiovascular Diseases (Cardiovascular Disease) 08/2021 - 08/2011
4	Mitochondrial Diseases (Mitochondrial Disease) 12/2023 - 06/2010
4	Ischemia 01/2022 - 04/2004
4	Hypoxia (Hypoxemia) 02/2020 - 03/2010
4	Hypertension (High Blood Pressure) 03/2013 - 01/2008
3	Necrosis 01/2023 - 04/2012
3	Vascular Diseases (Vascular Disease) 11/2022 - 03/2013
3	Hyperlipidemias (Hyperlipidemia) 01/2022 - 07/2014
3	Neoplasm Metastasis (Metastasis) 03/2010 - 06/2008
2	Hepatocellular Carcinoma (Hepatoma) 12/2023 - 08/2004
2	Glucose Intolerance 01/2023 - 01/2023
2	Cardiomegaly (Heart Hypertrophy) 01/2022 - 04/2012
2	Insulin Resistance 01/2021 - 03/2016
2	Fibrosis (Cirrhosis) 01/2021 - 01/2018
2	Type 2 Diabetes Mellitus (MODY) 01/2021 - 03/2016
2	Coronary Artery Disease (Coronary Atherosclerosis) 11/2020 - 01/2020
2	Cysts 10/2020 - 03/2013
2	Asthma (Bronchial Asthma) 10/2018 - 06/2009
2	Rheumatoid Arthritis 10/2018 - 11/2004
2	Hypercholesterolemia 10/2018 - 08/2011
2	Fatty Liver 11/2015 - 04/2009
2	Reperfusion Injury 06/2010 - 04/2004
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2023
1	Insulinoma 01/2023
1	Diabetes Mellitus 01/2023
1	Non-alcoholic Fatty Liver Disease 11/2022
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022

Drug/Important Bio-Agent (IBA)

17	LipidsIBA 11/2022 - 12/2002
13	Proteins (Proteins, Gene)FDA Link 01/2023 - 03/2006
12	CholesterolIBA 01/2023 - 05/2002
10	ApolipoproteinsIBA 01/2023 - 03/2010
10	CytokinesIBA 03/2021 - 09/2003
10	LDL Receptors (LDL Receptor)IBA 07/2014 - 02/2003
8	AntioxidantsIBA 05/2023 - 04/2004
7	Fenofibrate (CiL)FDA LinkGeneric 11/2022 - 12/2002
7	Apolipoproteins E (ApoE)IBA 03/2021 - 05/2012
6	PPAR alphaIBA 02/2009 - 12/2002
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2022 - 10/2012
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2019 - 04/2004
5	NF-kappa B (NF-kB)IBA 05/2005 - 08/2003
4	EnzymesIBA 01/2022 - 08/2011
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 08/2011
4	PeroxiredoxinsIBA 01/2022 - 09/2011
4	oxidized low density lipoproteinIBA 01/2020 - 10/2004
3	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 11/2022 - 03/2006
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022 - 10/2004
3	VimentinIBA 01/2022 - 01/2020
3	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2018
3	ResistinIBA 01/2021 - 01/2014
3	Superoxides (Superoxide)IBA 10/2020 - 05/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2020 - 02/2005
3	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 11/2016 - 03/2010
3	LigandsIBA 04/2012 - 10/2008
3	Peptides (Polypeptides)IBA 10/2011 - 10/2008
3	salicylhydroxamic acid (SHAM)IBA 10/2004 - 02/2003
3	Triglycerides (Triacylglycerol)IBA 05/2004 - 12/2002
2	Calcineurin InhibitorsIBA 01/2023 - 01/2023
2	Small Interfering RNA (siRNA)IBA 01/2023 - 06/2008
2	EndotoxinsIBA 01/2022 - 02/2014
2	Lipoproteins (Lipoprotein)IBA 01/2022 - 07/2014
2	Peroxidase (Myeloperoxidase)IBA 01/2022 - 09/2011
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 04/2013
2	CatalaseIBA 12/2019 - 09/2011
2	Bile Acids and Salts (Bile Acids)IBA 10/2018 - 11/2015
2	LDL CholesterolIBA 10/2018 - 11/2015
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2018 - 01/2017
2	Adenosine Triphosphatases (ATPase)IBA 12/2017 - 01/2008
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 02/2013 - 05/2012
2	AntibodiesIBA 02/2013 - 11/2006
2	Translationally-Controlled 1 Tumor ProteinIBA 12/2012 - 01/2008
2	Cilostazol (Pletal)FDA LinkGeneric 05/2012 - 05/2005
2	InterleukinsIBA 04/2012 - 09/2003
2	Glutathione Peroxidase GPX1IBA 09/2011 - 06/2010
2	Oxidoreductases (Dehydrogenase)IBA 08/2011 - 05/2004
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 11/2009 - 03/2006
2	Estrogens (Estrogen)FDA Link 02/2009 - 08/2003
2	CalciumIBA 02/2009 - 01/2008
1	Cardiolipins (Cardiolipin)IBA 12/2023
1	Diclofenac (SR 38)FDA LinkGeneric 12/2023
1	CaspasesIBA 12/2023
1	Insulin (Novolin)FDA Link 01/2023
1	RotenoneIBA 01/2023
1	HaptensIBA 01/2023
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2023
1	ChromatinIBA 01/2023
1	LuciferasesIBA 01/2023
1	2',5'-oligoadenylate (PAPAPA)IBA 11/2022
1	Messenger RNA (mRNA)IBA 11/2022
1	Alanine Transaminase (SGPT)IBA 11/2022

Therapy/Procedure

7	Therapeutics 02/2020 - 06/2010
1	Lasers (Laser) 01/2023
1	Transplantation 01/2023
1	Aftercare (After-Treatment) 01/2023